UnitedHealth Group shares plunge 18% on reported DOJ probe into possible Medicare fraud

UnitedHealth Group shares plunge 18% on reported DOJ probe into possible Medicare fraud


Bloomberg | Bloomberg | Getty Images

Shares of UnitedHealth Group plunged more than 18% on Thursday following a report that the Justice Department is conducting a criminal investigation into the health-care giant over possible Medicare fraud.

The DOJ is focusing on the company’s Medicare Advantage business practices, but the exact nature of the potential criminal allegations is unclear, the Wall Street Journal reported late Wednesday, citing people familiar with the matter. 

In a statement, UnitedHealth Group said the Justice Department has not notified it about the reported probe, and called the newspaper’s reporting “deeply irresponsible.”

The company also said “we stand by the integrity of our Medicare Advantage program.”

It marks the second time the insurer’s Medicare Advantage business has come under federal scrutiny this year. The Journal reported in February that the DOJ is carrying out a civil investigation into whether the company inflated diagnoses to trigger extra payments to its Medicare Advantage plans. 

The reported investigation also follows the surprise exit of UnitedHealth Group CEO Andrew Witty, who will be replaced by the company’s former longtime chief executive, Stephen Hemsley. 

Shares of UnitedHealth Group are down roughly 49% this year following a string of setbacks for the company.

UnitedHealth Group has lost over $300 billion of its $600 billion market cap in just one month, Jared Holz, Mizuho health care equity strategist, said in an email on Thursday. He said there is some risk that the company will be removed from the Dow Jones Industrial Average “at some point unless there is greater evidence of greater consistency.”

UnitedHealth Group also had a tumultuous last year, grappling with a historic cyberattack, higher-than-expected medical costs and the torrent of public blowback after the murder of UnitedHealthcare’s CEO Brian Thompson.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More